Cover Image

市場進入的課題:乾癬 (歐盟5國)

Market Access Impact (EU5) [PsO]

出版商 FirstWord 商品編碼 358482
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
Back to Top
市場進入的課題:乾癬 (歐盟5國) Market Access Impact (EU5) [PsO]
出版日期: 2017年03月01日 內容資訊: 英文

本報告依據歐盟5國 (法國、義大利、德國、西班牙、英國)的150名皮膚科醫生的乾癬治療藥的處方趨勢調查,提供關於處方集、償付、價格等,歐盟5國市場進入的障礙及影響因素,主要10個品牌比較分析、個別分析。


  • 市場進入的各種障礙
    • 醫生最大量開立處方的品牌為何?
    • 受到各種障礙影響的處方箋數是多少?
    • 哪個障礙影響最大?
  • 障礙對各品牌的影響
    • 開立各品牌處方的醫生數是多少?未開立處方但打算考慮數是多少?
    • 不開立處方的理由為何?其替代處方之物為何?
    • 各品牌的市場佔有率是多少?


  • Benepali (Etanercept:Biogen)
  • Cosentyx (secukinumab:Novartis)
  • Enbrel (Etanercept:Pfizer)
  • Humira (Adalimumab:AbbVie)
  • Inflectra (Infliximab:Pfizer)
  • Otezla (apremilast:Celgene)
  • Remicade (Infliximab:Merck Sharp & Dohme)
  • Remsima (Infliximab:Napp/Mundipharma)
  • Stelara (Ustekinumab:Janssen Cilag)
  • Taltz (ixekizumab:Eli Lilly)



Eliminating market barriers could lift the last place brand into the middle of the pack

In the EU5 countries, market barriers affect nearly a quarter of psoriasis prescriptions. Most of the brands we surveyed gain or lose a little bit of market share, but one brand is having a much harder time of it. If it can find a way to overcome market barriers, this brand could climb from dead last to somewhere in the middle of the pack.

Find out whether breaking down market barriers can give your brand a boost in Market Access Impact: Psoriasis (EU5).

Based on a survey of 150 dermatologists, the report covers 10 major therapies from AbbVie, Biogen, Celgene, EliLilly, Janssen Cilag, Merck Sharp & Dohme, Napp/Mundipharma, Novartis, and Pfizer. Handy graphs and charts reveal which of 7 different barriers cost your brand the most market share, and which ones help you take the most from competitors.

Top Takeaways

  • Barriers have a modest effect on surveyed brands: They affect nearly a quarter of prescriptions, but no surveyed brand gains or loses more than 2 percent of its share because of them.
  • "Other" brands see significant benefits: In aggregate, brands not surveyed see the largest barrier-related gain, putting them ahead of more than a third of surveyed brands.
  • Barriers are holding the last-place brand down: If barriers didn't exist, the last-place brand would climb to the middle of the pack.
  • The barrier effect is uneven: Several barriers have a big effect on a small number of brands, and less of an effect on the rest.
  • Many doctors don't experience barriers at all: 40 percent or more of surveyed doctors don't experience any barriers with most of the surveyed brands.
  • Several brands have perception problems: 14 to 24 percent of surveyed doctors either wouldn't consider prescribing them or simply don't know they exist.

Insight into 10 Major Psoriasis Drugs

  • Benepali (etanercept; Biogen)
  • Cosentyx (secukinumab; Novartis)
  • Enbrel (etanercept; Pfizer)
  • Humira (adalimumab; AbbVie)
  • Inflectra (infliximab; Pfizer)
  • Otezla (apremilast; Celgene)
  • Remicade (infliximab; Merck Sharp & Dohme)
  • Remsima (infliximab; Napp/Mundipharma)
  • Stelara (ustekinumab; Janssen Cilag)
  • Taltz (ixekizumab; Eli Lilly)

Exploring Important Market Access Issues

Market Access Impact: Psoriasis (EU5) explores key issues affecting drug manufacturers. You'll learn:

How barriers affect market access:

  • What brands do doctors prescribe the most?
  • How many prescriptions do barriers affect?
  • Which barriers have the biggest impact?

How barriers affect your brand:

  • How many doctors prescribe your brand? How many don't, but would consider it?
  • Why don't doctors prescribe your brand? What do they prescribe instead?
  • Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge

We surveyed 150 dermatologists-30 from each EU5 country (France, Italy, Germany, Spain, UK)-chosen from the largest community of validated physicians in the world.

All respondents have:

  • Been practicing for 2+ years
  • Prescribed at least one of the listed products
  • Seen at least 5 patients with psoriasis in total in the last month

We conducted the survey between February 1st and 7th, 2017.


At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company's success.

FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Table of Contents

1.What are market barriers?

2.About this report

3.About the survey

4.Brands included in the survey

5.Executive summary

Back to Top